Asad Haider
Stock Analyst at Goldman Sachs
(1.98)
# 3,066
Out of 4,962 analysts
7
Total ratings
50%
Success rate
8.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NAMS NewAmsterdam Pharma Company | Initiates: Neutral | $27 | $24.70 | +9.31% | 1 | Jul 17, 2025 | |
| BNTX BioNTech SE | Initiates: Neutral | $110 | $105.19 | +4.57% | 1 | May 29, 2025 | |
| JNJ Johnson & Johnson | Upgrades: Buy | $157 → $172 | $178.42 | -3.60% | 1 | Apr 9, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $695.42 | +27.69% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $207.49 | -6.50% | 1 | Apr 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $67 → $55 | $47.15 | +16.66% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $25.13 | -0.52% | 1 | Apr 8, 2025 |
NewAmsterdam Pharma Company
Jul 17, 2025
Initiates: Neutral
Price Target: $27
Current: $24.70
Upside: +9.31%
BioNTech SE
May 29, 2025
Initiates: Neutral
Price Target: $110
Current: $105.19
Upside: +4.57%
Johnson & Johnson
Apr 9, 2025
Upgrades: Buy
Price Target: $157 → $172
Current: $178.42
Upside: -3.60%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $695.42
Upside: +27.69%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $207.49
Upside: -6.50%
Bristol-Myers Squibb Company
Apr 8, 2025
Downgrades: Neutral
Price Target: $67 → $55
Current: $47.15
Upside: +16.66%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $25.13
Upside: -0.52%